Clinical chemistry, immunology and laboratory quality control : a comprehensive review for board preparation, certification and clinical practice / (Record no. 246860)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 09513cam a2200589Mi 4500 |
| 001 - CONTROL NUMBER | |
| control field | ocn879866913 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20190328114807.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr un|---uuuua |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 140429s2014 cauadf ob 001 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | GGVRL |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | GGVRL |
| Modifying agency | OCLCO |
| -- | GWM |
| -- | OCLCF |
| -- | YDXCP |
| -- | EBLCP |
| -- | OPELS |
| -- | N$T |
| -- | COO |
| -- | Z5A |
| -- | OCLCQ |
| -- | TEFOD |
| -- | ESU |
| -- | OCLCQ |
| -- | YDX |
| -- | CASUM |
| -- | OCLCQ |
| -- | U3W |
| -- | D6H |
| -- | WYU |
| 066 ## - CHARACTER SETS PRESENT | |
| Alternate G0 or G1 character set | (S |
| 019 ## - | |
| -- | 865333555 |
| -- | 870332576 |
| -- | 932129074 |
| -- | 956670909 |
| -- | 988823533 |
| -- | 1006797465 |
| -- | 1011200826 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780124079359 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 0124079350 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 0124078214 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780124078215 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)879866913 |
| Canceled/invalid control number | (OCoLC)865333555 |
| -- | (OCoLC)870332576 |
| -- | (OCoLC)932129074 |
| -- | (OCoLC)956670909 |
| -- | (OCoLC)988823533 |
| -- | (OCoLC)1006797465 |
| -- | (OCoLC)1011200826 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RB40 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | HEA |
| Subject category code subdivision | 039000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 014000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 022000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 112000 |
| Source | bisacsh |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 045000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.0756 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Dasgupta, Amitava, |
| Dates associated with a name | 1958- |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Clinical chemistry, immunology and laboratory quality control : a comprehensive review for board preparation, certification and clinical practice / |
| Medium | [electronic resource] |
| Statement of responsibility, etc. | Amitava Dasgupta, PhD, DABCC, Professor of Pathology and Laboratory Medicine, University of Texas Medical School at Houston, Amer Wahed, MD, Assistant Professor of Pathology and Laboratory Medicine, University of Texas Medical School at Houston. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | San Diego, CA : |
| Name of producer, publisher, distributor, manufacturer | Elsevier, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2014. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (xx, 483 pages, 4 unnumbered pages of plates) : |
| Other physical details | illustrations (some color) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Linkage | 880-01 |
| Formatted contents note | Chapter 1. Instrumentation and analytical methods -- chapter 2. Immunoassay platform and designs -- chapter 3. Pre-analytical variables -- chapter 4. Laboratory statistics and quality control -- chapter 5. Water, homeostasis, electrolytes, and acid-base balance -- chapter 6. Lipid metabolism and disorders -- chapter 7. Carbohydrate metabolism, diabetes, and hypoglycemia -- chapter 8. Cardiac markers -- chapter 9. Endocrinology -- chapter 10. Liver diseases and liver function tests -- chapter 11. Renal function tests -- chapter 12. Inborn errors of metabolism -- chapter 13. Tumor markers -- chapter 14. Therapeutic drug monitoring -- chapter 15. Interferences in therapeutic drug monitoring -- chapter 16. Drugs of abuse testing -- chapter 17. Challenges in drugs of abuse testing : magic mushrooms, peyote cactus, and designer drugs -- chapter 18. Testing for ethyl alcohol (alcohol) and other volatiles -- chapter 19. Common poisonings including heavy metal poisoning -- chapter 20. Pharmacogenomics -- chapter 21. Hemoglobinopathy -- chapter 22. Protein electrophoresis and immunofixation -- chapter 23. Human immunodeficiency virus (HIV) and hepatitis testing -- chapter 24. Autoimmunity, complement, and immunodeficiency -- chapter 25. Effect of herbal supplements on clinical laboratory test results. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | All pathology residents must have a good command of clinical chemistry, toxicology, immunology, and laboratory statistics to be successful pathologists, as well as to pass the American Board of Pathology examination. This book presents core topics and detailed case studies that illustrate the application of clinical chemistry knowledge to everyday patient care and offers practical examples of how things function in the pathology clinic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Clinical chemistry. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Clinical chemistry |
| Form subdivision | Case studies. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | HEALTH & FITNESS |
| General subdivision | Diseases |
| -- | General. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL |
| General subdivision | Clinical Medicine. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL |
| General subdivision | Diseases. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL |
| General subdivision | Evidence-Based Medicine. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | MEDICAL |
| General subdivision | Internal Medicine. |
| Source of heading or term | bisacsh |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Clinical chemistry. |
| Source of heading or term | fast |
| Authority record control number | (OCoLC)fst00864330 |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 655 #7 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Case studies. |
| Source of term | fast |
| Authority record control number | (OCoLC)fst01423765 |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wahed, Amer, |
| Relator term | author. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Dasgupta, Amitava. |
| Title | Clinical Chemistry, Immunology and Laboratory Quality Control : A Comprehensive Review for Board Preparation, Certification and Clinical Practice. |
| Place, publisher, and date of publication | Burlington : Elsevier Science, �2013 |
| International Standard Book Number | 9780124078215 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Materials specified | ScienceDirect |
| Uniform Resource Identifier | http://www.sciencedirect.com/science/book/9780124078215 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Materials specified | ScienceDirect |
| Uniform Resource Identifier | https://www.sciencedirect.com/science/book/9780124078215 |
| 880 00 - ALTERNATE GRAPHIC REPRESENTATION | |
| Linkage | 505-01/(S |
| g | 8.8. |
| t | B-Type Natriuretic Peptides (BNP) -- |
| g | 8.9. |
| t | C-Reactive Protein -- |
| g | 8.10. |
| t | Myeloperoxidase -- |
| -- | Key Points -- |
| -- | References -- |
| g | 9.1. |
| t | Introduction to Various Endocrine Glands -- |
| g | 9.2. |
| t | Hypothalamus -- |
| g | 9.3. |
| t | Pituitary Gland -- |
| g | 9.4. |
| t | Thyroid Gland -- |
| g | 9.5. |
| t | Thyroid Function Tests -- |
| g | 9.6. |
| t | Hypothyroidism -- |
| g | 9.7. |
| t | Hyperthyroidism -- |
| g | 9.8. |
| t | Disorders of Parathyroid Glands -- |
| g | 9.9. |
| t | Adrenal Glands -- |
| g | 9.10. |
| t | Cushing's Syndrome -- |
| g | 9.11. |
| t | Conn's Syndrome -- |
| g | 9.12. |
| t | Hypoadrenalism Including Addison's Disease -- |
| g | 9.13. |
| t | Dysfunctions of Gonads -- |
| g | 9.14. |
| t | Pancreatic Endocrine Disorders -- |
| g | 9.15. |
| t | Multiple Endocrine Neoplasias -- |
| g | 9.16. |
| t | Endocrine Testings: Suppression and Stimulation Tests -- |
| -- | Key Points -- |
| -- | References -- |
| g | 10.1. |
| t | Liver Physiology -- |
| g | 10.2. |
| t | Liver Function Tests and Interpretations -- |
| g | 10.3. |
| t | Jaundice: An Introduction -- |
| g | 10.4. |
| t | Congenital Hyperbilirubinemia -- |
| g | 10.5. |
| t | Hemolytic (Prehepatic) Jaundice -- |
| g | 10.6. |
| t | Hepatocellular Jaundice -- |
| g | 10.7. |
| t | Chronic Liver Disease -- |
| g | 10.8. |
| t | Cholestatic Jaundice -- |
| g | 10.9. |
| t | Alcohol- and Drug-Induced Liver Disease -- |
| g | 10.10. |
| t | Liver Disease in Pregnancy -- |
| g | 10.11. |
| t | Liver Disease in Neonates and Children -- |
| g | 10.12. |
| t | Macro Liver Enzymes -- |
| g | 10.13. |
| t | Laboratory Measurement of Bilirubin and Other Tests -- |
| -- | Key Points -- |
| -- | References -- |
| g | 11.1. |
| t | Basic Functions of Kidneys -- |
| g | 11.2. |
| t | Glomerular Filtration Rate -- |
| g | 11.3. |
| t | Creatinine Clearances -- |
| g | 11.4. |
| t | Chronic Kidney Disease -- |
| g | 11.5. |
| t | Cystatin C -- |
| g | 11.6. |
| t | Urea (Blood Urea Nitrogen) and Uric Acid -- |
| g | 11.7. |
| t | Protein in Urine and Proteinuria -- |
| g | 11.8. |
| t | Other Renal Diseases -- |
| g | 11.9. |
| t | Laboratory Measurements of Creatinine and Related Tests -- |
| g | 11.10. |
| t | Urine Dipstick Analysis -- |
| -- | Key Points -- |
| -- | References -- |
| g | 12.1. |
| t | Overview of Inborn Errors of Metabolism -- |
| g | 12.2. |
| t | Amino Acid Disorders -- |
| g | 12.2.1. |
| t | Phenylketonuria -- |
| g | 12.2.2. |
| t | Maple Syrup Urine Disease (MSUD) -- |
| g | 12.2.3. |
| t | Other Amino Acid Disorders -- |
| g | 12.3. |
| t | Carbohydrate Metabolism Disorders -- |
| g | 12.3.1. |
| t | Galactosemia -- |
| g | 12.3.2. |
| t | Glycogen Storage Disease -- |
| g | 12.3.3. |
| t | Fructose Intolerance -- |
| g | 12.3.4. |
| t | Lactose Intolerance -- |
| g | 12.4. |
| t | Urea Cycle Disorders -- |
| g | 12.5. |
| t | Organic Acid Disorders (Organic Aciduria) -- |
| g | 12.6. |
| t | Fatty Acid Oxidation Disorders -- |
| g | 12.7. |
| t | Mitochondrial Disorders -- |
| g | 12.8. |
| t | Peroxisomal Disorders -- |
| g | 12.9. |
| t | Lysosomal Storage Disorders -- |
| g | 12.10. |
| t | Purine or Pyrimidine Metabolic Disorders -- |
| g | 12.11. |
| t | Disorders of Porphyrin Metabolism -- |
| g | 12.12. |
| t | Newborn Screening and Evaluation -- |
| -- | Key Points -- |
| -- | References -- |
| g | 13.1. |
| t | Introduction to Tumor Markers -- |
| g | 13.2. |
| t | Clinical Uses of Tumor Markers and Common Tumor Markers -- |
| g | 13.3. |
| t | Prostate-Specific Antigen (PSA) -- |
| g | 13.4. |
| t | False Positive and Unexpected PSA Results -- |
| g | 13.5. |
| t | Cancer Antigen 125 (Carbohydrate Antigen 125: CA-125) -- |
| g | 13.6. |
| t | False Positive CA-125 -- |
| g | 13.7. |
| t | Alpha-Fetal Protein -- |
| g | 13.8. |
| t | False Positive AFP -- |
| g | 13.9. |
| t | Carcinoembryonic Antigen (CEA) -- |
| g | 13.10. |
| t | False Positive CEA -- |
| g | 13.11. |
| t | Cancer Antigen-19-9 -- |
| g | 13.12. |
| t | (Sb(B2-Microglobulin -- |
| g | 13.13. |
| t | Human Chorionic Gonadotropin (hCG) -- |
| g | 13.14. |
| t | Causes and Evaluation of Persistent Low Levels of hCG -- |
| g | 13.15. |
| t | False Positive hCG -- |
| -- | Key Points -- |
| -- | References -- |
| g | 14.1. |
| t | What is Therapeutic Drug Monitoring-- |
| g | 14.2. |
| t | Drugs That Require Therapeutic Drug Monitoring -- |
| g | 14.3. |
| t | Free Versus Total Drug Monitoring -- |
| g | 14.4. |
| t | Therapeutic Drug Monitoring Benefits -- |
| g | 14.5. |
| t | Basic Pharmacokinetics -- |
| g | 14.6. |
| t | Effect of Gender and Pregnancy on Drug Metabolism and Disposition -- |
| g | 14.7. |
| t | Effect of Age on Drug Metabolism and Disposition -- |
| g | 14.8. |
| t | Drug Metabolism and Disposition in Uremia -- |
| g | 14.9. |
| t | Drug Metabolism and Disposition in Liver Disease -- |
| g | 14.10. |
| t | Effect of Cardiovascular Disease on Drug Metabolism and Disposition -- |
| g | 14.11. |
| t | Thyroid Dysfunction and Drug Metabolism -- |
| g | 14.12. |
| t | Effect of Food, Alcohol Consumption, and Smoking on Drug Disposition -- |
| g | 14.13. |
| t | Monitoring of Various Drug Classes: General Considerations -- |
| g | 14.14. |
| t | Monitoring of Anticonvulsants -- |
| g | 14.15. |
| t | Monitoring of Cardioactive Drugs -- |
| g | 14.16. |
| t | Monitoring of Anti-Asthmatic Drugs -- |
| g | 14.17. |
| t | Monitoring of Antidepressants -- |
| g | 14.18. |
| t | Monitoring of Immunosuppressants -- |
| g | 14.19. |
| t | Monitoring of Selected Antibiotics -- |
| g | 14.20. |
| t | Monitoring of Antineoplastic Drugs -- |
| g | 14.21. |
| t | Monitoring of Antiretrovirals -- |
| -- | Key Points -- |
| -- | References -- |
| g | 15.1. |
| t | Methodologies Used in Therapeutic Drug Monitoring and Issues of Interferences -- |
| g | 15.2. |
| t | Effect of Endogenous Factors on Therapeutic Drug Monitoring -- |
| g | 15.3. |
| t | Effect of Collecting Specimen in Gel-Separator Tube on Therapeutic Drug Monitoring Results -- |
| g | 15.4. |
| t | Digoxin Immunoassays: So Much Interference -- |
| g | 15.5. |
| t | Interferences in Analysis of Antiepileptics -- |
| g | 15.6. |
| t | Interferences in Analysis of Tricyclic Antidepressants -- |
| g | 15.7. |
| t | Interferences in Analysis of Immunosuppressants. |
No items available.